Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

Please go ahead. Joe Crivelli: Hello, and thanks for joining us to discuss Vertex's third quarter financial results. I'm Joe ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

As Vertex looks to tap into the Middle Eastern market of around 23,000 patients—on top of its estimated patient pool of 35,000 in the U.S. and Europe—the drugmaker remains “confident in our ...

So when a business like Vertex Pharmaceuticals (NASDAQ: VRTX) releases some new data on a potential blockbuster that could be just a few months away from being approved for sale, it's a big ...

Federal Territory of Kuala Lumpur, Malaysia - November 5, 2024 — SurgeGraph, one of the leading AI writing tools, today ...

Please go ahead. Hello, and thanks for joining us to discuss Vertex's third quarter financial results. I'm Joe Crivelli, Vice President, Investor Relations. David DeStefano, our President and CEO ...